Results 101 to 110 of about 4,546,141 (355)
Adverse events related to blood transfusion
The acute blood transfusion reactions are responsible for causing most serious adverse events. Awareness about various clinical features of acute and delayed transfusion reactions with an ability to assess the serious reactions on time can lead to a ...
S. Sahu, Hemlata, A. Verma
semanticscholar +1 more source
ABSTRACT Although living‐donor liver transplantation (LDLT) has become the standard treatment for end‐stage liver disease, one of its major challenges is small‐for‐size syndrome (SFSS). SFSS is characterized by severe icterus and intractable ascites, although the severity of the condition can vary.
Toru Ikegami+6 more
wiley +1 more source
SPLENECTOMY FOR LACERATED SPLEEN, AFTER BLOOD TRANSFUSION [PDF]
Arthur H. Bogart
openalex +1 more source
Characterizing the Healthcare Utilization and Costs of Hereditary Hemorrhagic Telangiectasia
ABSTRACT Hereditary hemorrhagic telangiectasia (HHT) is the second‐most common inherited bleeding disorder worldwide, afflicting one in 4000–5000 people, and is the most morbid inherited bleeding disorder of women. HHT causes recurrent severe epistaxis, chronic gastrointestinal bleeding, heavy menstrual bleeding, and arteriovenous malformations in the ...
Hanny Al‐Samkari+5 more
wiley +1 more source
Effect of Blood Transfusion on Rheumatoid Arthritis [PDF]
N. R. W. Simpson+2 more
openalex +1 more source
ABSTRACT Cardiovascular complications are the leading cause of mortality in sickle cell anemia (SCA) patients. While extensive data have identified diastolic dysfunction (DD) to increase morbidity and mortality, the unique hemodynamic conditions inherent to SCA challenge the current recommendations to assess diastolic function. Thus, there is an urgent
Théo Simon+20 more
wiley +1 more source
An Instrument for the Transfusion of Defibrinated Blood [PDF]
Thomas Wharton Jones
openalex +1 more source
ABSTRACTHereditary hemorrhagic telangiectasia (HHT, Osler‐Weber‐Rendu disease) is the second most common inherited bleeding disorder worldwide, affecting approximately 1 in 5000 people. Development of disease‐modifying and efficacious hemostatic agents to treat HHT has finally begun after decades without such medical therapies.
Hanny Al‐Samkari+22 more
wiley +1 more source
VENESECTION AND BLOOD TRANSFUSION IN CARBON MONOXIDE POISONING [PDF]
Charles Gordon‐Watson
openalex +1 more source